Robert F. Apple, Chief Operating Officer
InKine Pharmaceutical Company, Inc.

Donald C. Weinberger
Wolfe Axelrod Weinberger Assoc. LLC
212-370-4500, 212-370-4505 fax
[email protected]



BLUE BELL, PA March 18, 2004 - InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) ) announced that Leonard S. Jacob, M.D., Ph.D., Chairman and Chief Executive Officer of InKine is scheduled to appear on CNBC’s “Kudlow and Cramer” today, March 18, 2004. Jim Cramer and Lawrence Kudlow host the show, which is broadcast live from 5 PM to 6 PM EST on CNBC. With Colorectal Cancer Awareness Month underway, Dr. Jacob is expected to discuss the importance of colorectal cancer awareness and screening.

The American Cancer Society estimates that 146,940 cases of colorectal cancer will be diagnosed in 2004 and 56,730 deaths will occur. Colorectal cancer is the second leading cause of cancer death in the United States, yet it is highly preventable and treatable with simple screening exams such as colonoscopy. A recent published study cited that liquid bowel preparations are the most common deterrent to patients undergoing colonoscopy screening. InKine is the manufacturer of Visicol® tablets, the first and only FDA approved, patient preferred, tablet purgative indicated for bowel cleansing prior to colonoscopy.

About InKine Pharmaceutical
InKine Pharmaceutical Company, Inc. is a publicly traded biopharmaceutical company focused on the diagnosis and treatment of cancer and autoimmune diseases. The Company's development strategy is to acquire late-stage drug candidates with short time lines to commercialization. The Company's first product, Visicol™ is the first and only tablet purgative preparation indicated for bowel cleansing prior to colonoscopy. InKine's second product, IBStat™, is a novel oral hysocyamine spray for the treatment of Irritable Bowel Syndrome (IBS) and spasm of the colon. Additionally, the Company is developing other clinical compounds such as Colirest™, which is in clinical trials for the treatment of Crohn's disease and completed Phase II trials for the treatment of ulcerative colitis. For further information, please visit InKine on their web site http://www.inkine.com.

In addition to historical facts or statement of current condition, this press release may contain forward-looking statements. Forward-looking statements provide InKine's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings projections, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. InKine's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties such as those set forth in its reports on Form 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, InKine does not intend (and it is not obligated) to update publicly any forward-looking statements. This discussion is permitted by the Private Securities Litigation Reform Act of 1995.